KMO and neurodegenerative disease: In a transgenic Drosophila melanogaster model of Huntington’s disease, UPF648 was shown to mitigate disease-relevant phenotypes, providing the first genetic evidence in animal models that KMO inhibition can sequentially lead to protection against neurodegenerative diseases and other disorders that result from the overactive stimulation of the kynurenine pathway.